AMAG Pharma (AMAG) Reports Q1 Loss of $3.54/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
AMAG Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 7:01 AM EDTAchieved record Feraheme revenue growth and more than 50% market share for Makena auto-injector
Completed integration of Perosphere Pharmaceuticals Inc. and progressed ciraparantag clinical program
Reaffirms 2019 financial guidance
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the first quarter ended March 31, 2019 and provided a business update.
Total revenue for the first quarter of 2019 was $75.8 million, compared with $117.4 million in the same period last year. Makena®... More
